Elanco Animal Health Inc (ELAN) company profile
Close on Nov 17, 2026Market cap $12.92BP/E –Yield –
About Elanco Animal Health
Pharmaceutical Preparations, SIC 2834
Elanco Animal Health Incorporated develops, manufactures, and markets products to prevent and treat disease in pets and farm animals. Operating as a single segment within the animal health industry, the company provides treatments primarily for dogs, cats, cattle, poultry, swine, and sheep. Its product line encompasses parasiticides, dermatology treatments, vaccines, pain management therapeutics, medicated feed additives, injectable antibiotics, and enzymes. Elanco distributes its pet care offerings to third-party distributors, retailers, and veterinary clinics, while its farm animal products are supplied to commercial distributors and livestock producers.
The company sells its portfolio across more than 90 countries, with the United States representing its largest market alongside key international markets in Brazil, the United Kingdom, and China. Global commercial operations are supported by 16 manufacturing facilities situated across eight countries, as well as an extensive network of contract manufacturing organizations and international research and development sites. Elanco maintains its research and development headquarters in Indianapolis, Indiana.
Summary of the business section of Elanco Animal Health's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Elanco Animal Health Inc
- Founded
- 1954
- Headquarters
- Indianapolis, IN
- Address
- 450 Elanco Circle 46221
- Phone
- (877) 352-6261
- Website
- www.elanco.com
- Employees
- 9,400, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Indianapolis, Indiana
Stock & identifiers
- Ticker
- ELAN
- Exchange
- NYSE
- IPO date
- Sep 21, 2018
- Shares outstanding
- 500M, Aug 3, 2026
- Public float
- $7.00B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1739104
- CUSIP
- 28414H103
- ISIN
- US28414H1032
- FIGI
- BBG00LJYS1P8
- Share class FIGI
- BBG00LJYS1R6
- LEI
- 549300SHPNDCE059M934
- EIN
- 82-5497352
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jeffrey N. Simmons | PRESIDENT, CEO AND DIRECTOR | 2,223,869 |
| Robert M. VanHimbergen | EVP and CFO | 137,516 |
| Rajeev A. Modi | SEE REMARKS | 160,812 |
| Jamie Preston | EVP, Chief People Officer | – |
| Timothy J. Bettington | SEE REMARKS | 138,911 |
| Shiv O'Neill | GC AND CORP SEC | 87,832 |
| David S. Kinard | SEE REMARKS | 214,264 |
| Brabander Ellen de | SEE REMARKS | 280,821 |
| de Simas Jose Manuel Correia | SEE REMARKS | 101,017 |
| Grace McArdle | EVP, MANUFACTURING AND QUALITY | 103,705 |
| Ramiro Martin Cabral | SEE REMARKS | 283,874 |
| James M. Meer | CHIEF ACCOUNTING OFFICER | 66,732 |
| Todd S. Young | SEE REMARKS | 369,839 |
| Kapila K. Anand | Director | 111,847 |
| Lawrence Erik Kurzius | Director | 188,647 |
| Michael J. Harrington | Director | 131,451 |
| Paul Herendeen | Director | 111,687 |
| Deborah Turner Kochevar | Director | 94,392 |
| Denise Scots-Knight | Director | 93,392 |
| R. David Hoover | Director | 277,371 |
| Art A. Garcia | Director | 108,152 |
| Kirk P. McDonald | Director | 105,588 |
| Stacey Ma | Director | 17,531 |
| Kathy V. Turner | Director | 13,838 |
| Craig S. Wallace | Director | 13,838 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $14.93M | $37.81M | $3.83M | $74 | $188 |
| FY2024 | $14.83M | $9.23M | $3.37M | $39 | $148 |
| FY2023 | $13.66M | $17.32M | $3.03M | $49 | $137 |
| FY2022 | $12.71M | -$2.02M | $2.78M | $40 | $136 |
| FY2021 | $12.06M | $16.53M | $3.20M | $93 | $126 |
| FY2020 | $8.96M | $9.32M | $2.15M | $104 | $108 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Jeffrey Simmons President and CEO | $1.20M | – | $9.00M | $3.00M | $1.70M | $25.35K | $14.93M | +1% |
| Robert VanHimbergen Executive Vice President and Chief Financial Officer | $317.31K | $890.00K | $2.29M | $550.00K | $539.55K | $79.42K | $4.66M | – |
| Ellen de Brabander Executive Vice President, Innovation and Regulatory | $847.83K | – | $1.72M | $572.00K | $739.31K | $36.08K | $3.91M | -0% |
| Ramiro Cabral Executive Vice President, President International | $650.00K | – | $1.50M | $500.00K | $566.80K | $26.95K | $3.24M | +10% |
| Timothy Bettington Executive Vice President, Center for Strategic Growth | $656.00K | – | $1.05M | $350.01K | $500.53K | $26.95K | $2.58M | +2% |
| Todd Young Former Executive Vice President and Chief Financial Officer | $477.10K | – | $2.18M | $725.00K | – | $1.38M | $4.75M | +16% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Sep 21, 2018
- Offer price
- $24.00
- Securities offered
- 62,900,000
- Gross proceeds
- $1.51B
- Exchange
- NYSE
- Lock-up ends (est.)
- Mar 20, 2019
“The initial public offering price per share is $24.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed approximately 9,400 full time employees and approximately 500 fixed-duration employees, which are individuals hired for a pre-defined length of time (typically one to four years).”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 9, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 1, 2023 | Delisting | Notice of delisting from exchange (Form 25) |
| Aug 3, 2020 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 27, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
| May 30, 2019 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| May 17, 2019 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Feb 8, 2019 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Sep 21, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| Sep 18, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?